Tg Therapeuticscmn (TGTX) 6.18 $TGTX Walgreens Boots

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Tg Therapeuticscmn (TGTX) 6.18 $TGTX

Walgreens Boots Tops Q3 Earnings, Rite Aid Deal on Track
Zacks Equity Research - Zacks Investment Research - Wed Jul 06, 10:46AM CDT
Walgreens Boots (WBA) reported a mixed third-quarter fiscal 2016 with earnings comfortably beating the Zacks Consensus Estimate, while the top line closely missed the mark.
ICUI: 114.80 (-0.20), WBA: 82.16 (+0.36), GWPH: 95.48 (+0.65), TGTX: 6.18 (+0.02)

Chronic Lymphocytic Leukemia Market to Grow at 19% CAGR to 2020
PR Newswire Europe - Thu Jun 23, 7:30AM CDT
PUNE, India, June 23, 2016 /PRNewswire/ --
TGTX: 6.18 (+0.02)

TG Therapeutics, Inc. Announces Data from TGR-1202 in Combination with Ibrutinib as well as Recaps Long-Term Safety and Efficacy Data of TGR-1202 in CLL and NHL at the 21st European Hematology Association Annual Congress
GlobeNewswire - Fri Jun 10, 8:15AM CDT
TG Therapeutics, Inc. (NASDAQ:TGTX) today announced data presented during the 21 Annual Congress of the European Hematology Association (EHA) being held in Copenhagen, Denmark. These presentations include long term follow-up data of TGR-1202, the Company's once daily PI3K delta inhibitor, both alone and in combination with TG-1101 (ublituximab), the Company's novel glycoengineered anti-CD20 monoclonal antibody, as well as data presented for the first time from a Phase I/Ib study of TGR-1202 in combination with ibrutinib in patients with relapsed/refractory CLL or MCL.
TGTX: 6.18 (+0.02)

TG Therapeutics, Inc. to Present at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Thu Jun 09, 6:30AM CDT
TG Therapeutics, Inc. (Nasdaq:TGTX) today announced that Michael S. Weiss, the Company's Executive Chairman and Interim Chief Executive Officer, will present at the Jefferies 2016 Healthcare Conference being held at the Grand Hyatt in New York, NY. The presentation is scheduled to take place on Friday June 10, 2016 at 10:00am PT. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com.
TGTX: 6.18 (+0.02)

TG Therapeutics, Inc. Announces First Patient Enrolled in the Registration-Directed UNITY-DLBCL Phase 2b Trial
GlobeNewswire - Tue Jun 07, 6:30AM CDT
TG Therapeutics, Inc. (NASDAQ:TGTX) today announced the enrollment of its first patient in its registration-directed UNITY-DLBCL Phase 2b clinical study evaluating TG-1101, the Company's novel glycoengineered anti-CD20 monoclonal antibody, in combination with TGR-1202, the Company's orally available PI3K delta inhibitor, as well as TGR-1202 alone, in patients with previously treated Diffuse Large B-Cell Lymphoma (DLBCL).
TGTX: 6.18 (+0.02)

TG Therapeutics, Inc. Announces Long-Term Follow-up of TGR-1202 Demonstrates a Differentiated Safety Profile and High Response Rates in CLL and NHL in Data Presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
GlobeNewswire - Mon Jun 06, 8:00AM CDT
High response rates observed across CLL, DLBCL & indolent NHL
TGTX: 6.18 (+0.02)

TG Therapeutics, Inc. Recaps Schedule of Clinical Data Presentations at the 52nd Annual Meeting of the American Society of Clinical Oncology
GlobeNewswire - Thu Jun 02, 6:30AM CDT
TG Therapeutics, Inc. (Nasdaq:TGTX) today recapped the schedule of data presentations at the 52 Annual Meeting of the American Society of Clinical Oncology (ASCO), to be held from June 3 - 7, 2016, at McCormick Place in Chicago, Illinois.
TGTX: 6.18 (+0.02)

TG Therapeutics Enters into a Global Collaboration to Develop and Commercialize Novel BET Inhibitors Developed by Jubilant Biosys for the Treatment of Hematological Malignancies
GlobeNewswire - Fri May 27, 6:30AM CDT
TG Therapeutics, Inc. (Nasdaq:TGTX), announced today that as part of a broader agreement with Jubilant Biosys ("Jubilant", an Indian biotechnology company, TG Therapeutics entered into a sub-license agreement with Checkpoint Therapeutics, Inc. ("Checkpoint", a Fortress Biotech company, to develop and commercialize Jubilant's novel BET inhibitor program in the field of hematological malignancies. Checkpoint will develop and commercialize these small molecule inhibitors in solid tumors. The BET inhibitor program is the subject of an exclusive, worldwide license agreement pursuant to which Checkpoint in-licensed from Jubilant a family of patents covering compounds that inhibit BRD4, a member of the BET (Bromodomain and Extra Terminal) domain for cancer treatment.
TGTX: 6.18 (+0.02)

TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 21st European Hematology Association Annual Congress
GlobeNewswire - Fri May 20, 6:30AM CDT
TG Therapeutics, Inc. (Nasdaq:TGTX), today announced that updated data has been selected for presentation at the upcoming 21 European Hematology Association (EHA) Annual Congress, to be held from June 9 - 12, 2016 in Copenhagen, Denmark.
TGTX: 6.18 (+0.02)

TG Therapeutics, Inc. Announces Clinical Data Presentation at the Upcoming 52nd Annual Meeting of the American Society of Clinical Oncology
GlobeNewswire - Wed May 18, 4:15PM CDT
TG Therapeutics, Inc. (Nasdaq:TGTX), today announced that updated data has been selected for presentation at the upcoming 52 Annual Meeting of the American Society of Clinical Oncology (ASCO), to be held from June 3 - 7, 2016, at McCormick Place in Chicago, Illinois.
TGTX: 6.18 (+0.02)

TG Therapeutics, Inc. Announces First Quarter 2016 Financial Results and Business Update
GlobeNewswire - Tue May 10, 3:00PM CDT
TG Therapeutics, Inc. (NASDAQ:TGTX) today announced its financial results for the first quarter ended March 31, 2016 and recent company developments.
TGTX: 6.18 (+0.02)

TG Therapeutics, Inc. to Host Conference Call on First Quarter 2016 Financial Results and Business Update
GlobeNewswire - Mon May 09, 6:30AM CDT
TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that a conference call will be held on Tuesday, May 10, 2016 at 4:30pm ET to discuss results for the first quarter of 2016 and provide a business outlook for the remainder of the year. Michael S. Weiss, Executive Chairman and Interim Chief Executive Officer, will host the call.
TGTX: 6.18 (+0.02)

TG Therapeutics, Inc. Launches First Clinical Trial in Multiple Sclerosis (MS) for TG-1101 (Ublituximab)
GlobeNewswire - Tue May 03, 6:30AM CDT
Phase 2 study commenced to determine optimal dosing regimen in Relapsing MS patients
TGTX: 6.18 (+0.02)

TG Therapeutics, Inc. Announces Pre-Clinical Data Presentation on TGR-1202 Demonstrating Differentiated Effects on T-Cells
GlobeNewswire - Mon Apr 18, 6:35AM CDT
Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2016 compares TGR-1202 to other PI3K-delta inhibitors, providing preliminary mechanism for differentiated clinical safety observed to date
TGTX: 6.18 (+0.02)

TG Therapeutics, Inc. Announces Issuance of Composition of Matter Patent for TG-1101 in the United States
GlobeNewswire - Wed Apr 13, 6:30AM CDT
TG Therapeutics, Inc. (Nasdaq:TGTX) today announced that the United States Patent and Trademark Office (USPTO) has issued a patent for the composition of matter of TG-1101, the Company's novel, glycoengineered monoclonal antibody. The patent, U.S. Patent No. 9,234,045 specifically covers the composition of TG-1101, and its use for treating various forms of CD20 expressing leukemia and lymphoma, including chronic lymphocytic leukemia (CLL) and various types of non-Hodgkin's lymphoma, including follicular lymphoma (FL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), and diffuse large B-cell lymphoma (DLBCL).
TGTX: 6.18 (+0.02)

TG Therapeutics, Inc. Announces Pre-Clinical Data Presentation on TGR-1202 at the 2016 American Association for Cancer Research (AACR) Annual Meeting
GlobeNewswire - Thu Mar 17, 6:30AM CDT
TG Therapeutics, Inc. (Nasdaq:TGTX) today announced that preclinical data describing the differential regulation of human T-cells by TGR-1202 was selected for poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2016, to be held April 16 - 20, 2016 at the Ernest N. Morial Convention Center in New Orleans, Louisiana. The data, which was developed as part of an ongoing research collaboration with the H. Lee Moffitt Cancer Center and Research Institute in Tampa, FL, compares TGR-1202 with the PI3K-delta inhibitors idelalisib and duvelisib in in-vitro models assessing the impact on T-cell subsets.
TGTX: 6.18 (+0.02)

TG Therapeutics, Inc. to Present at the 28th Annual ROTH Conference
GlobeNewswire - Fri Mar 11, 3:30PM CST
TG Therapeutics, Inc. (Nasdaq:TGTX) today announced that Michael S. Weiss, the Company's Executive Chairman and Interim Chief Executive Officer, will present at the 28 Annual ROTH Conference, being held at the Ritz Carlton in Laguna Niguel, CA. The presentation is scheduled to take place on Tuesday March 15, 2016 at 3:30pm PT. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com.
TGTX: 6.18 (+0.02)

TG Therapeutics reports 4Q loss
Automated Insights - Mon Mar 07, 3:39PM CST
NEW YORK (AP) _ TG Therapeutics Inc. (TGTX) on Monday reported a loss of $17.6 million in its fourth quarter.
TGTX: 6.18 (+0.02)

TG Therapeutics, Inc. Announces Fourth Quarter and Year-End 2015 Financial Results and Business Update
GlobeNewswire - Mon Mar 07, 3:00PM CST
Ended 2015 in a Strong Financial Position, With More Than $100 Million in Cash and Investments
TGTX: 6.18 (+0.02)

Investor Calendar Invites You to the TG Therapeutics, Inc. Fourth Quarter and Fiscal Year 2015 Earnings Conference Call and Webcast Live on Monday, March 7, 2016
ACCESSWIRE - Mon Mar 07, 7:00AM CST
NEW YORK, NY / ACCESSWIRE / March 7, 2016 / TG Therapeutics, Inc. (NASDAQ: TGTX) will host a live conference call and webcast to discuss the results of the fourth quarter and fiscal year 2015, to be held today, Monday, March 7, 2016 at 4:30 PM Eastern Time.
TGTX: 6.18 (+0.02)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 208

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 308

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 241

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 245

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 485

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 374

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 284

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 334

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 272

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 374

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading

Top 5 Most Recently Viewed Articles

How Recent Tax Changes Favor Robinhood Markets in Gambling

Updated Category News Views 1112

How Recent Tax Changes Favor Robinhood Markets in Gambling A small detail in recent legislation has the potential to transform the landscape of professional sports betting across the U.S. The One Big Beautiful Bill (OBBB) Act introduces a shift in tax policy that impacts how professional gamblers are taxed compared to stock and options traders. Under this new framework,...

Continue Reading
Bloomberg Launches Generative AI for Enhanced Document Analysis

Updated Category News Views 851

Revolutionizing Financial Research with AI Innovations Bloomberg has taken a significant step forward in financial analysis with the introduction of AI-Powered Document Insights. This innovative solution enables research analysts and corporate decision-makers to ask complex questions and receive insightful answers from company documents using everyday conversational...

Continue Reading
Sidus Space Sees Remarkable Stock Growth After Key Announcements

Updated Category News Views 153

Why Is Sidus Space Stock Surging? Sidus Space (NASDAQ: SIDU) has caught the attention of investors with its impressive stock surge, recently climbing to $2.87, a rise of $0.67 or about 30.45%. This remarkable movement in share price follows notable announcements by the company. Significant Financing Through Public Offering On December 24, Sidus Space revealed that it had...

Continue Reading
Kuraray's Strategic Move: Acquiring Nelumbo for Growth

Updated Category News Views 348

Kuraray Expands Its Horizons with Nelumbo Acquisition Kuraray Co., Ltd. has embarked on an exciting journey by acquiring Nelumbo Inc., a forward-thinking company known for its unique materials technology for surface modification. Although the financial details of this acquisition remain confidential, the strategic implications are substantial. Discovering Nelumbo’s...

Continue Reading
Appfire Appoints Matt Dircks as New CEO for Future Growth

Updated Category News Views 682

Exciting Leadership Change at Appfire In a significant move for Appfire, the company has appointed Matt Dircks as its new CEO, succeeding founding leader Randall Ward. This change represents a pivotal moment for Appfire as it looks to elevate its growth trajectory, fueled by a solid vision and strategic direction. Randall Ward's Legacy and Transition Randall Ward, who has...

Continue Reading